Literature DB >> 19705064

MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules.

Zhixiang Zhang1, Tao Meng, Jingxue He, Ming Li, Lin-Jiang Tong, Bing Xiong, Liping Lin, Jingkang Shen, Ze-Hong Miao, Jian Ding.   

Abstract

Targeting cellular mitosis is an attractive antitumor strategy. Here, we reported MT7, a novel compound from the 6H-Pyrido[2',1':2,3]imidazo [4,5-c]isoquinolin- 5(6H)-one library generated by using the multi-component reaction strategy, as a new mitotic inhibitor. MT7 elicited apparent inhibition of cell proliferation by arresting mitosis specifically and reversibly in various tumor cell lines originating from different human tissues. Detailed mechanistic studies revealed that MT7 induced typical gene expression profiles related to mitotic arrest shown by cDNA microarray assays. Connectivity Map was used to analyze the microarray data and suggested that MT7 was possibly a tubulin inhibitor due to its similar gene expression profiles to those of the known tubulin inhibitors demecolcine, celastrol and paclitaxel. Further analyses demonstrated that MT7 inhibited the polymerization of cellular microtubules although it was not detectable to bind to purified tubulin. The inhibition of cellular tubulin polymerization by MT7 subsequently resulted in the disruption of mitotic spindle formation, activated the spindle assembly checkpoint and consequently arrested the cells at mitosis. The persistent mitotic arrest by the treatment with MT7 led the tested tumor cells to apoptosis. Our data indicate that MT7 could act as a promising lead for further optimization, in hopes of developing new anticancer therapeutics and being used to probe the biology of mitosis, specifically, the mode of interference with microtubules.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19705064     DOI: 10.1007/s10637-009-9303-z

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  54 in total

1.  Analysis of the spindle-assembly checkpoint in HeLa cells.

Authors:  Paul R Andreassen; Dimitrios A Skoufias; Robert L Margolis
Journal:  Methods Mol Biol       Date:  2004

2.  Microtubule regulation in mitosis: tubulin phosphorylation by the cyclin-dependent kinase Cdk1.

Authors:  Anne Fourest-Lieuvin; Leticia Peris; Vincent Gache; Isabel Garcia-Saez; Céline Juillan-Binard; Violaine Lantez; Didier Job
Journal:  Mol Biol Cell       Date:  2005-12-21       Impact factor: 4.138

3.  Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.

Authors:  K Tanabe; Y Ikegami; R Ishida; T Andoh
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

4.  Microtubule assembly in the absence of added nucleotides.

Authors:  M L Shelanski; F Gaskin; C R Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  1973-03       Impact factor: 11.205

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins.

Authors:  P B Schiff; S B Horwitz
Journal:  Biochemistry       Date:  1981-05-26       Impact factor: 3.162

7.  Antimitotic quinoid triterpenes from Maytenus chuchuhuasca.

Authors:  Hiroshi Morita; Yusuke Hirasawa; Akihiro Muto; Tadashi Yoshida; Setsuko Sekita; Osamu Shirota
Journal:  Bioorg Med Chem Lett       Date:  2007-12-15       Impact factor: 2.823

8.  Mitotic transcription repression in vivo in the absence of nucleosomal chromatin condensation.

Authors:  C A Spencer; M J Kruhlak; H L Jenkins; X Sun; D P Bazett-Jones
Journal:  J Cell Biol       Date:  2000-07-10       Impact factor: 10.539

9.  Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks.

Authors:  Diego di Bernardo; Michael J Thompson; Timothy S Gardner; Sarah E Chobot; Erin L Eastwood; Andrew P Wojtovich; Sean J Elliott; Scott E Schaus; James J Collins
Journal:  Nat Biotechnol       Date:  2005-03       Impact factor: 54.908

10.  Cyclin A is required at two points in the human cell cycle.

Authors:  M Pagano; R Pepperkok; F Verde; W Ansorge; G Draetta
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

View more
  5 in total

1.  Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin.

Authors:  Ting Peng; Jian-Rui Wu; Lin-Jiang Tong; Meng-Yuan Li; Fang Chen; Yi-Xin Leng; Rong Qu; Kun Han; Yi Su; Yi Chen; Wen-Hu Duan; Hua Xie; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2014-05-26       Impact factor: 6.150

2.  Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.

Authors:  Jun-Mei Yi; Xiao-Fei Zhang; Xia-Juan Huan; Shan-Shan Song; Wei Wang; Qian-Ting Tian; Yi-Ming Sun; Yi Chen; Jian Ding; Ying-Qing Wang; Chun-Hao Yang; Ze-Hong Miao
Journal:  Oncotarget       Date:  2015-04-20

3.  Human factors and pathways essential for mediating epigenetic gene silencing.

Authors:  Andrey Poleshko; Andrew V Kossenkov; Natalia Shalginskikh; Anna Pecherskaya; Margret B Einarson; Anna Marie Skalka; Richard A Katz
Journal:  Epigenetics       Date:  2014-08-04       Impact factor: 4.528

4.  Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells.

Authors:  Claire Levrier; Anja Rockstroh; Brian Gabrielli; Maria Kavallaris; Melanie Lehman; Rohan A Davis; Martin C Sadowski; Colleen C Nelson
Journal:  Cell Cycle       Date:  2018       Impact factor: 4.534

5.  A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning Predictions.

Authors:  Francesco Iorio; Roshan L Shrestha; Nicolas Levin; Viviane Boilot; Mathew J Garnett; Julio Saez-Rodriguez; Viji M Draviam
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.